Aurelius Omlin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aurelius Omlin has a total of 299 co-authors. Here are the top co-authors by number of shared publications:
- Silke Gillessen
Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Faculty of Biosciences, Università della Svizzera Italiana, Lugano, Switzerland
30 shared publications - Richard Cathomas
Division of Oncology/Hematology, Kantonsspital Graubünden, Chur, Switzerland
21 shared publications - Anja Lorch
Department of Urology, University Hospital, Duesseldorf, Germany
18 shared publications - Axel Heidenreich
Department of Urology, Urologic Oncology, Robot‐Assisted and Specialized Urologic Surgery University of Cologne Cologne Germany
18 shared publications - Christoph Reuter
University Hospital, Hannover, Germany
18 shared publications - Gunhild von Amsberg
University Cancer Center Hamburg and Martini-Klinik, University Hospital Hamburg Eppendorf, Hamburg, Germany
18 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (10) , 1043
Correction to: Prevalence of meeting aerobic physical activity and resistance training guidelines in advanced prostate cancer: a descriptive study of racial and regional disparities in the IRONMAN registry
- 2 October 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (10) , 1043
Open AccessCorrection to: Prevalence of meeting aerobic physical activity and resistance training guidelines in advanced prostate cancer: a descriptive study of racial and regional disparities in the IRONMAN registry
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
Representativeness of Study Participants
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
Representativeness of Study Participants
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
Purpose:There is ongoing controversy about the recommended dose of cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC).Patients and Methods:This multicenter phase II open-label, randomized, parallel-group study compared 3-weekly cabazitaxel at 25 mg/m2 (conventional arm A) with cabazitaxel therapeutic drug monitoring (experimental arm B) in mCRPC. The primary objective was to improve the clinical feasibility rate (CFR), defined as the absence of grade 4 neutropenia or thrombocytopenia, any thrombocytopenia with bleeding, febrile neutropenia, severe nonhematologic toxicity, withdrawal for cabazitaxel-related toxicity, or death. A total of 60 patients had to be randomized to detect a difference in CFR of 35% (power 80%, two-sided alpha 10%).Results:A total of 40 patients were randomized to arm A and 33 patients to arm B. CFR was 69.4% in arm A and 64.3% in arm B (P = 0.79). Week-12 PSA response was 38.5% in both arms. A radiological response by RECIST v.1.1 was seen in 3 (9.7%) patients in arm A versus 6 (23.1%) patients in arm B (P = 0.28), disease progression was higher in arm A compared with arm B (61.3% vs. 30.8%, P = 0.05). Median progression-free survival was longer in arm B compared with arm A (9.5 vs. 4.4 months; HR = 0.46; P = 0.005). Median overall survival was higher in arm B compared with arm A (16.2 vs. 7.3 months; HR = 0.33; P < 0.0001).Conclusions:Pharmacokinetic-guided dosing of cabazitaxel in patients with mCRPC is feasible and improves clinical outcome due to individual dose escalations in 55% of patients.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
Purpose:There is ongoing controversy about the recommended dose of cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC).Patients and Methods:This multicenter phase II open-label, randomized, parallel-group study compared 3-weekly cabazitaxel at 25 mg/m2 (conventional arm A) with cabazitaxel therapeutic drug monitoring (experimental arm B) in mCRPC. The primary objective was to improve the clinical feasibility rate (CFR), defined as the absence of grade 4 neutropenia or thrombocytopenia, any thrombocytopenia with bleeding, febrile neutropenia, severe nonhematologic toxicity, withdrawal for cabazitaxel-related toxicity, or death. A total of 60 patients had to be randomized to detect a difference in CFR of 35% (power 80%, two-sided alpha 10%).Results:A total of 40 patients were randomized to arm A and 33 patients to arm B. CFR was 69.4% in arm A and 64.3% in arm B (P = 0.79). Week-12 PSA response was 38.5% in both arms. A radiological response by RECIST v.1.1 was seen in 3 (9.7%) patients in arm A versus 6 (23.1%) patients in arm B (P = 0.28), disease progression was higher in arm A compared with arm B (61.3% vs. 30.8%, P = 0.05). Median progression-free survival was longer in arm B compared with arm A (9.5 vs. 4.4 months; HR = 0.46; P = 0.005). Median overall survival was higher in arm B compared with arm A (16.2 vs. 7.3 months; HR = 0.33; P < 0.0001).Conclusions:Pharmacokinetic-guided dosing of cabazitaxel in patients with mCRPC is feasible and improves clinical outcome due to individual dose escalations in 55% of patients.
- Open Access
- 22 November 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 233, 116131
A roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024
- 22 November 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 233, 116131
Open AccessA roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024
- 1 August 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500310
Activity of Platinum Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer and DNA Damage Repair Gene Alterations
PURPOSE: Up to 30% of patients with metastatic castration-resistant prostate cancer (mCRPC) have DNA damage repair (DDR) gene alterations, mainly in BRCA2 . PARP inhibitors (PARPi) are standard treatments for BRCA1/2 -altered patients with mCRPC, and evidence for platinum agents is limited. This study assesses single-agent platinum therapy in patients with mCRPC with and without DDR alterations. METHODS: This multicenter, retrospective study included patients with mCRPC with known DDR status treated with platinum monotherapy. DDR-positive (DDR+) patients had deleterious germline or somatic alterations in DDR genes ( BRCA1 , BRCA2 , CDK12 , ATM , CHEK2 , PALB2 , or FANCA ), whereas DDR-negative (DDR–) patients had no such alterations. Prostate-specific antigen (PSA) response, progression-free survival (PFS, PSA/clinical/radiographic), and overall survival (OS) were assessed in DDR+ and DDR– groups. RESULTS: Among 129 patients, 81 had DDR+ and 48 had DDR– cancers. A PSA decline of ≥50% was demonstrated in 48% in BRCA, 9% in DDR+ non-BRCA, and 13% in DDR– patients ( P < .0001). Objective responses occurred in 37.5% in BRCA, 11% in DDR+ non-BRCA, and 13% in DDR– patients ( P = .017). No response was reported in DDR+ patients who had received previous PARPi (n = 16). The median PSA response was 5 months for BRCA, 2 months for DDR+ non-BRCA, and 1.7 months for DDR– patients, respectively ( P = .015), whereas the median clinical/radiographic PFS was 4.7 months, 2.8 months, and 2 months, respectively ( P = .2). In PARPi-naïve patients, the median OS was 13.7 months for BRCA, 8.7 months for DDR+ non-BRCA, and 6.1 months for DDR– patients ( P = .013). CONCLUSION: Single-agent platinum agents show significant anticancer activity in BRCA -mutated patients with mCRPC without previous PARPi exposure. With their low cost and broad availability, platinum agents offer a practical alternative, particularly in regions where PARPi are inaccessible.
- 1 August 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500310
Activity of Platinum Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer and DNA Damage Repair Gene Alterations
PURPOSE: Up to 30% of patients with metastatic castration-resistant prostate cancer (mCRPC) have DNA damage repair (DDR) gene alterations, mainly in BRCA2 . PARP inhibitors (PARPi) are standard treatments for BRCA1/2 -altered patients with mCRPC, and evidence for platinum agents is limited. This study assesses single-agent platinum therapy in patients with mCRPC with and without DDR alterations. METHODS: This multicenter, retrospective study included patients with mCRPC with known DDR status treated with platinum monotherapy. DDR-positive (DDR+) patients had deleterious germline or somatic alterations in DDR genes ( BRCA1 , BRCA2 , CDK12 , ATM , CHEK2 , PALB2 , or FANCA ), whereas DDR-negative (DDR–) patients had no such alterations. Prostate-specific antigen (PSA) response, progression-free survival (PFS, PSA/clinical/radiographic), and overall survival (OS) were assessed in DDR+ and DDR– groups. RESULTS: Among 129 patients, 81 had DDR+ and 48 had DDR– cancers. A PSA decline of ≥50% was demonstrated in 48% in BRCA, 9% in DDR+ non-BRCA, and 13% in DDR– patients ( P < .0001). Objective responses occurred in 37.5% in BRCA, 11% in DDR+ non-BRCA, and 13% in DDR– patients ( P = .017). No response was reported in DDR+ patients who had received previous PARPi (n = 16). The median PSA response was 5 months for BRCA, 2 months for DDR+ non-BRCA, and 1.7 months for DDR– patients, respectively ( P = .015), whereas the median clinical/radiographic PFS was 4.7 months, 2.8 months, and 2 months, respectively ( P = .2). In PARPi-naïve patients, the median OS was 13.7 months for BRCA, 8.7 months for DDR+ non-BRCA, and 6.1 months for DDR– patients ( P = .013). CONCLUSION: Single-agent platinum agents show significant anticancer activity in BRCA -mutated patients with mCRPC without previous PARPi exposure. With their low cost and broad availability, platinum agents offer a practical alternative, particularly in regions where PARPi are inaccessible.
- Open Access
Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors
Background: Immune checkpoint inhibitors (ICIs) improve overall survival (OS) in advanced/metastatic urothelial cancer (a/mUC) patients. Preliminary evidence suggests a prognostic role of inflammatory biomarkers in this setting. We aimed to develop a disease-specific prognostic inflammatory index for a/mUC patients on ICIs. Methods: Fifteen variables were retrospectively correlated with OS and progression-free survival (PFS) in a development (D, n = 264) and a validation (V, n = 132) cohort of platinum-pretreated a/mUC pts receiving ICIs at L2 or further line. A nomogram and inflammatory prognostic index (U-IPI) were developed. The index was also tested in a control cohort of patients treated with chemotherapy only (C, n = 114). Results: The strongest predictors of OS were baseline platelet/lymphocyte (PLR) and neutrophil/lymphocyte (NLR) ratios, and lactate dehydrogenase (LDH), NLR, and albumin changes at 4 weeks. These were used to build the U-IPI, which can distinctly classify patients into good or poor response groups. The nomogram scoring is significant for PFS and OS (p < 0.001 in the D, V, and combined cohorts) for the immunotherapy (IO) cohort, but not for the control cohort. Conclusions: The lack of a baseline systemic inflammatory profile and the absence of early serum inflammatory biomarker changes are associated with significantly better outcomes on ICIs in a/mUC pts. The U-IPI is an easily applicable dynamic prognostic tool for PFS and OS, allowing for the early identification of a sub-group with dismal outcomes that would not benefit from ICIs, while distinguishing another that draws an important benefit.
Open AccessDevelopment and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors
Background: Immune checkpoint inhibitors (ICIs) improve overall survival (OS) in advanced/metastatic urothelial cancer (a/mUC) patients. Preliminary evidence suggests a prognostic role of inflammatory biomarkers in this setting. We aimed to develop a disease-specific prognostic inflammatory index for a/mUC patients on ICIs. Methods: Fifteen variables were retrospectively correlated with OS and progression-free survival (PFS) in a development (D, n = 264) and a validation (V, n = 132) cohort of platinum-pretreated a/mUC pts receiving ICIs at L2 or further line. A nomogram and inflammatory prognostic index (U-IPI) were developed. The index was also tested in a control cohort of patients treated with chemotherapy only (C, n = 114). Results: The strongest predictors of OS were baseline platelet/lymphocyte (PLR) and neutrophil/lymphocyte (NLR) ratios, and lactate dehydrogenase (LDH), NLR, and albumin changes at 4 weeks. These were used to build the U-IPI, which can distinctly classify patients into good or poor response groups. The nomogram scoring is significant for PFS and OS (p < 0.001 in the D, V, and combined cohorts) for the immunotherapy (IO) cohort, but not for the control cohort. Conclusions: The lack of a baseline systemic inflammatory profile and the absence of early serum inflammatory biomarker changes are associated with significantly better outcomes on ICIs in a/mUC pts. The U-IPI is an easily applicable dynamic prognostic tool for PFS and OS, allowing for the early identification of a sub-group with dismal outcomes that would not benefit from ICIs, while distinguishing another that draws an important benefit.
- 27 March 2024
- Published by Georg Thieme Verlag KG in Aktuelle Urologie
- Vol. 55 (02) , e1
Erratum: Sequenztherapie des kastrationsresistenten Prostatakarzinoms: Evidenzbasierte klinische Algorithmen
Im oben genannten Artikel wurde Abb.1 aktualisiert. Die Korrektur wurde in der Onlineversion des Artikels ausgeführt am: Article published online: 06 June 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 27 March 2024
- Published by Georg Thieme Verlag KG in Aktuelle Urologie
- Vol. 55 (02) , e1
Erratum: Sequenztherapie des kastrationsresistenten Prostatakarzinoms: Evidenzbasierte klinische Algorithmen
Im oben genannten Artikel wurde Abb.1 aktualisiert. Die Korrektur wurde in der Onlineversion des Artikels ausgeführt am: Article published online: 06 June 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 27 March 2024
- Published by Georg Thieme Verlag KG in Aktuelle Urologie
- Vol. 55 (02) , 161-173
Sequenztherapie des kastrationsresistenten Prostatakarzinoms: Evidenzbasierte klinische Algorithmen
Wenn sich bei Patienten mit fortgeschrittenem Prostatakarzinom unter der Androgendeprivation (ADT) eine Krankheitsprogredienz abzeichnet, spricht man von Kastrationsresistenz. Die Therapiewahl in dieser Situation richtet sich nach den bereits vorgängig durchgeführten Behandlungen, Ausdehnung und Dynamik der Erkrankung, Faktoren wie Krankheitssymptomatik und Lebensqualität, Komorbiditäten und Komedikationen und nicht zuletzt auch individuellen Wünschen des betroffenen Patienten. Article published online: 27 March 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 27 March 2024
- Published by Georg Thieme Verlag KG in Aktuelle Urologie
- Vol. 55 (02) , 161-173
Sequenztherapie des kastrationsresistenten Prostatakarzinoms: Evidenzbasierte klinische Algorithmen
Wenn sich bei Patienten mit fortgeschrittenem Prostatakarzinom unter der Androgendeprivation (ADT) eine Krankheitsprogredienz abzeichnet, spricht man von Kastrationsresistenz. Die Therapiewahl in dieser Situation richtet sich nach den bereits vorgängig durchgeführten Behandlungen, Ausdehnung und Dynamik der Erkrankung, Faktoren wie Krankheitssymptomatik und Lebensqualität, Komorbiditäten und Komedikationen und nicht zuletzt auch individuellen Wünschen des betroffenen Patienten. Article published online: 27 March 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1. from Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer
A table showing baseline characteristics at enrollment of individuals with advanced prostate cancer in IRONMAN, by outcome status (N=2,119).
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1. from Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer
A table showing baseline characteristics at enrollment of individuals with advanced prostate cancer in IRONMAN, by outcome status (N=2,119).